SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it kicks off public deliveries for the R2 midsize SUV, with investors intensely debating whether the launch marks a pivotal shift toward profitability or just another "sell-the-news" event. The community is sharply divided between those cheering the R2's positive reviews and partnerships with firms like Uber, and those frustrated by continued cash burn, management's communication style, and the stock's persistent volatility.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining momentum as market participants increasingly highlight its status as an established meme with original IP rights and a growing community presence. Investors are actively drawing parallels to past major market cycles while debating its potential for future growth alongside other prominent meme-sector assets.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is gaining significant traction due to its expanded role in institutional payment infrastructure, highlighted by recent integrations with banking giants and the growth of tokenized real-world assets on the XRP Ledger. Community discourse remains highly active, fueled by the launch of spot ETFs and growing optimism regarding the clarity of digital asset regulations.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is under intense market scrutiny following an FDA clinical hold placed on its RGX-111 and RGX-121 gene therapy programs due to a tumor found in a trial participant. The community is actively debating the implications for the February 8 PDUFA date for RGX-121, with many fearing a delay or rejection despite the company's efforts to advance its broader pipeline.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is trending as investors digest news that the FDA has identified deficiencies in a competitors new drug application, effectively clearing a near-term runway for its needle-free epinephrine product. The community is actively discussing the potential for a major short squeeze, as the stock remains heavily shorted with a constrained float and growing global commercial momentum.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing high volatility as investors weigh a aggressive multi-year production ramp for AI-driven data center transceivers against steep valuation premiums and recent insider selling. While bullish sentiment focuses on the company's vertical integration and ability to navigate supply chain bottlenecks, bearish voices highlight execution risks and concerns over whether current price levels have already fully priced in long-term growth expectations.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense discussion driven by its high volatility and community debates regarding its long-term viability versus its identity as a meme-heavy speculative asset. Investors are actively tracking its correlation with other memecoins and comparing it to broader market trends as sentiment remains sharply divided between those calling for a breakout and those warning of a total collapse.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders rotate back into AI and IoT-linked tokens, with the community closely tracking potential ecosystem expansion and technical breakout patterns. Sentiment remains divided between long-term holders betting on utility-driven adoption in Japan and skeptical traders who view recent price action as speculative volatility.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors debate the regulatory path for AXPAXLI, with community discussions heavily focused on the company's strategy for NDA submission based on single-trial data and potential M&A interest. While some shareholders remain optimistic about a buyout or partnership following strong clinical data, others are raising concerns over competitive legal threats, market volatility, and the timeline for upcoming investor presentations.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate its long-term potential as a reliable payment-focused digital asset versus its recent price underperformance compared to other crypto coins. The community is intensely focused on technical indicators, potential institutional interest, and the network's resilience as they watch for a breakout from current consolidation levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer

(RTTNews) - AstraZeneca's (AZN,AZN.L,ZEG.DE,AZN.ST) Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-na?ve or...

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.

Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?

Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.

Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case

MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.read more...

JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.

LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials

Equity

Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.


AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, supporting regulatory filings.read more...

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

AZNAstraZeneca PLC

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AZN News